<DOC>
	<DOCNO>NCT01011218</DOCNO>
	<brief_summary>Primary Objective : 1 . To provide preliminary data effect armodafinil Brief Behavioral Therapy Insomnia ( BBT-I ) ( alone combination ) insomnia breast cancer patient receive chemotherapy . Secondary Objectives : 1 . To provide preliminary data influence armodafinil BBT-I ( alone combination ) cancer-related fatigue ( CRF ) breast cancer patient receive chemotherapy . 2 . To provide preliminary data influence armodafinil BBT-I ( alone combination ) QOL breast cancer patient receive chemotherapy . 3 . To provide preliminary data influence armodafinil BBT-I ( alone combination ) endocrine inflammatory physiological marker ( measure cortisol inflammatory cytokine marker )</brief_summary>
	<brief_title>Management Insomnia Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Be schedule planned cancer treatment chemotherapy biologics , Herceptin ( prior chemotherapy diagnosis metastatic breast allow ) Have least 6 week treatment remain Be least 21 year old Be able swallow medication Exhibit onset worsen problem fall stay asleep Have ever take armodafinil modafinil Have unstable medical psychiatric illness ( Axis I current within last 5 year ) Have history uncontrolled cardiac disease , hypertension , severe headache , glaucoma , seizure Have take psychostimulant medication within past 28 day Be currently pregnant nurse Have history substance abuse meet criterion current alcohol abuse dependence Have selfreported history chronic , preexist insomnia , sleep apnea , RLS syndrome Have take sleep medication daily last 28 day continuously Have severe hepatic impairment Be take antiseizure medication</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>quality life</keyword>
</DOC>